Dogwood Therapeutics, Inc. (DWTX) Stock Forecast
DWTX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 2 analysts
- Price target
- $14.00 average of analyst targets
- Upside to target
- +1,047.5% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.15
- 52-week range
- $1.22 – $6.82
DWTX analyst ratings
2 analystsNumber of analysts at each rating.
DWTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DWTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.15 | −$0.16 | −$0.15 | −$8.20 | +98.1% | 2 |
| Current fiscal year (2026) | −$0.88 | −$0.95 | −$0.80 | −$7.13 | +87.7% | 2 |
| Next fiscal year (2027) | −$0.64 | −$0.78 | −$0.47 | −$0.88 | +27.2% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DWTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 3 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 3 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 3 |
DWTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DWTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.14 | −$0.14 | −$0.14 | −$0.15 | −26.2% | 0 up · 2 down |
| Current fiscal year (2026) | −$0.82 | −$0.58 | −$0.58 | −$0.58 | −$0.88 | +6.3% | 0 up · 2 down |
| Next fiscal year (2027) | −$0.99 | −$0.65 | −$0.65 | −$0.65 | −$0.64 | −35.9% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DWTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DWTX beat in 5 of 12.
What analysts expect from DWTX
2 analysts cover Dogwood Therapeutics; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $14.00, 1,047.5% above the latest close of $1.22. Analysts expect earnings of −$0.88 per share for 2026, +87.7% from a year earlier. For 2027 the average estimate is −$0.64 per share. Dogwood Therapeutics beat the EPS estimate in 5 of the last 12 quarters.
Related: DWTX income statement, DWTX key metrics, DWTX chart. See the DWTX stock overview for the latest quote and news.
DWTX forecast FAQ
What is Dogwood Therapeutics's price target?
The average analyst price target for Dogwood Therapeutics is $14.00, 1,047.5% above the latest close of $1.22.
Is Dogwood Therapeutics a buy, hold or sell?
Of 2 analysts covering Dogwood Therapeutics, 1 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Dogwood Therapeutics's EPS forecast?
Analysts forecast −$0.88 per share for 2026 (range −$0.95 to −$0.80); for 2027 the estimate is −$0.64.
When does Dogwood Therapeutics report earnings?
Dogwood Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $-0.15.
Does Dogwood Therapeutics usually beat earnings estimates?
Dogwood Therapeutics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.